Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision cancer therapies using innovative genetic approaches. Founded in 2017, the company utilizes CRISPR technology and the principles of synthetic lethality to target genetically defined cancers. Under the leadership of CEO Barbara Weber, Tango focuses on expanding access to genetically targeted therapies by identifying specific vulnerabilities in cancer cells. The company employs CRISPR-driven target discovery to validate novel cancer targets and maintains a growing pipeline of preclinical and clinical programs aimed at addressing unmet needs in oncology. Tango's approach integrates synthetic lethality and CRISPR screening to design selective therapies and emphasizes precision medicine for patient subsets with limited treatment options. Through strategic collaborations, Tango Therapeutics aims to advance its drug candidates and transition them into clinical testing within a few years.